The pharmaceutical industry's core bottleneck is molecular simulation. To design a drug, researchers must understand how a candidate molecule will interact with a specific protein target a calculation involving quantum mechanical interactions between thousands of electrons across complex molecular structures.
Classical computers approximate these calculations using simplified models. The approximations introduce errors that accumulate, meaning classical molecular simulation is fundamentally limited in accuracy for large, complex molecules.
Why Quantum Changes Everything
Quantum computers simulate quantum systems natively. A quantum processor modeling molecular interactions doesn't approximate quantum mechanics it uses quantum mechanics. The computational advantage for molecular simulation is not theoretical; it's fundamental.
For a protein with N atoms, classical simulation complexity scales approximately as O(N³) to O(N⁸) depending on the accuracy required. Quantum simulation scales as O(poly(N)) a qualitative difference that becomes decisive for molecules with more than ~50 atoms.
Most drug targets involve proteins with hundreds to thousands of atoms. For these problems, classical simulation is simply not possible at required accuracy levels. Quantum simulation is.
The STELLAR Orbital Quantum Advantage
Our 128-qubit orbital quantum processor, operating with 10x the coherence time of terrestrial systems, can simulate molecular systems that are completely inaccessible to ground-based quantum computers. Longer coherence times directly translate to more complex quantum circuits meaning more atoms, more electron interactions, and more realistic molecular models.
Target Applications
Protein Folding and Function: Predicting how a protein folds and how it changes shape when bound to a candidate drug is the central computational challenge in drug design. Our quantum processor can model folding pathways for proteins that currently require approximation methods.
Binding Affinity Prediction: Accurately predicting how strongly a drug molecule binds to its target allows researchers to filter billions of candidate molecules computationally before ever synthesizing a single compound. This compresses the years-long screening process into weeks.
Toxicity Prediction: Many drug candidates fail in clinical trials due to unexpected toxicity. Quantum simulation of metabolic pathways can identify toxic metabolites before human trials.
The economic prize is enormous. The global pharmaceutical market is $1.5 trillion annually. A 10x compression in discovery timelines, applied even to 10% of drug programs, represents $150B/year in value creation. STELLAR's orbital quantum platform is positioned to capture a significant fraction of this value.